Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) (NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/ .
This report is prepared based on the principles of the Corporate Governance Code as in effect as of June 1, 2018. Takeda will submit a revised Corporate Governance Report based on the Corporate Governance Code as in effect as of June 11, 2021, by the end of December 2021.
Takeda’s latest Corporate Governance Report can be found at the information disclosure site operated by the Japan Exchange Group which consists of the TSE and other exchanges in Japan at:
Takeda also furnished the English version of the Corporate Governance Report with the U.S. Securities and Exchange Commission (the “SEC”), available at www.sec.gov .
As for the general information about the Corporate Governance Report, please refer to the Japan Exchange Group website at: https://www.jpx.co.jp/english/equities/listing/cg/01.html .
Additionally, Takeda’s corporate governance policy as well as overall Environmental, Social and Governance information is explained in detail in its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. This report can be accessed on Takeda’s website at: https://air.takeda.com
*TSE’s Securities Listing Regulations [Rule 419].
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REYKJAVIK-EDITION21.10.2021 17:32:13 CEST | Press release
The Spotlight on Iceland’s Capital City Shines Even Brighter With the Arrival of The Reykjavik EDITION
VEWD21.10.2021 16:43:08 CEST | Press release
MediaTek Selected to Power Vewd for Automotive Platform
BIOGNOSYS21.10.2021 16:02:05 CEST | Press release
Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference
SIGFOX21.10.2021 16:02:05 CEST | Press release
SHV Energy Implements Global Remote LPG Tank Monitoring With Sigfox Netherlands’ 0G Network and Reduces Carbon Emissions
NEWSIGHT21.10.2021 15:52:04 CEST | Press release
SSZN Selects Newsight's NSI1000 Chip for Its Advanced Industry 4.0 Production Line Sensors
WA-ESPER/LENOVO21.10.2021 15:07:08 CEST | Press release
Esper and Lenovo Collaborate on Android Device Deployment in Enterprises
CA-XPRIZE21.10.2021 15:02:07 CEST | Press release
Finalist Teams Selected in $10M ANA Avatar XPRIZE Competition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom